CASSAVA SCIENCES INC. - COMMON STOCK

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

10 май 2024 16:02:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

08 май 2024 11:00:00 Источник Nasdaq GlobeNewswire

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

01 май 2024 09:10:00 Источник Nasdaq GlobeNewswire

Redemption Date Announced for Warrants

15 апр 2024 09:20:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

25 мар 2024 09:13:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

04 мар 2024 09:15:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

28 фев 2024 09:14:00 Источник Nasdaq GlobeNewswire

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

07 фев 2024 09:08:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

05 янв 2024 09:12:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

12 дек 2023 09:13:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Appoints Three New Members to its Board of Directors

07 дек 2023 16:01:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

07 ноя 2023 09:01:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

06 ноя 2023 09:15:00 Источник Nasdaq GlobeNewswire

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

25 окт 2023 09:15:00 Источник Nasdaq GlobeNewswire

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

12 окт 2023 23:43:21 Источник Nasdaq GlobeNewswire

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

05 окт 2023 09:15:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

02 окт 2023 09:00:44 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

18 сен 2023 09:15:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

11 сен 2023 09:10:00 Источник Nasdaq GlobeNewswire

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

06 сен 2023 09:15:00 Источник Nasdaq GlobeNewswire